Peptilogics, Inc.
Industry
- Pharmaceuticals
- Digital Health
- Artificial Intelligence
- Biotechnology
- Drug Discovery Technologies
Latest on Peptilogics, Inc.
Some three years after COVID-19 kickstarted a massive adoption of digital technology and shift to remote monitoring in clinical development, technology continues to effect seismic changes in the trial
The first half of 2022 saw the NASDAQ Biotechnology Index lose a quarter of its value. Despite a tentative recovery since then, the IPO window is barely ajar and valuations remain well below the highs
Peptilogics, Inc. is planning a 2026 US filing of its lead asset in an orphan orthopedic indication as it works to validate its AI platform that can design peptides with enhanced risk-benefit profile
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Ovid Taps Gensaic’s Approach To Neurolo